维生素 D 补充对非酒精性脂肪性肝病患者某些代谢参数的影响：8 项 RCT 的系统评价和荟萃分析。

The effect of vitamin D supplementation on some metabolic parameters in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 8 RCTs.

机构信息

Department of Public Health, International College, Krirk University, Bangkok, Thailand.

School of Architecture & Art Design, Hebei University of Technology, Tianjin, China.

出版信息

Medicine (Baltimore). 2023 Oct 20;102(42):e35717. doi: 10.1097/MD.0000000000035717.

DOI:10.1097/MD.0000000000035717

PMID:37861495

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10589544/

Abstract

BACKGROUND

To systematically evaluate the effects of vitamin D supplementation in patients with nonalcoholic fatty liver disease (NAFLD).

METHODS

National Library of Medicine, Cochrane Library, Elsevier, China National Knowledge Infrastructure, Web of Science, WANFANG databases, and Google Scholar were retrieved to collect relevant randomized controlled trials, which are published from the earliest records the time the database was created to April 2023. Meta-analysis was conducted by using Review Manager 5.4 software after evaluating in terms of inclusion and exclusion criteria. The outcome indicators include 25-hydroxyvitamin D [25(OH)D] levels, insulin resistance index (homeostasis model assessment of insulin resistance), fasting blood glucose, and fasting insulin levels (FINS).

RESULTS

Eight randomized controlled trials with a total of 657 patients are included. Vitamin D supplementation increased 25(OH)D levels significantly (mean difference [MD] = 2.01, 95% confidence intervals [CI]: 0.94 to 3.08, P < .05) and vitamin D supplementation had a significant effect on insulin resistance index (MD = -0.54, 95% CI: -1.28 to 0.20, P = .16), fasting glucose (MD = -0.59, 95% CI: -1.50 to 0.32, P = .20), and FINS levels (MD = -0.30, 95% CI: -0.77 to 0.17, P = .21) had no significant effect.

CONCLUSION

Vitamin D supplementation improves 25(OH)D levels in patients with nonalcoholic fatty liver disease, but there is no effect on homeostasis model assessment of insulin resistance, fasting blood glucose, or FINS.

摘要

背景

系统评价维生素 D 补充剂对非酒精性脂肪性肝病（NAFLD）患者的影响。

方法

检索美国国立医学图书馆、考科兰协作网、爱思唯尔、中国知网、Web of Science、万方数据库和谷歌学术，收集从各数据库建库时间至 2023 年 4 月发表的关于维生素 D 补充剂治疗非酒精性脂肪性肝病的随机对照试验。采用 Review Manager 5.4 软件进行 Meta 分析，评价纳入研究的纳排标准。结局指标包括 25-羟维生素 D [25(OH)D]水平、胰岛素抵抗指数（稳态模型评估的胰岛素抵抗）、空腹血糖和空腹胰岛素水平（FINS）。

结果

共纳入 8 项随机对照试验，总计 657 例患者。维生素 D 补充剂可显著提高 25(OH)D 水平（均数差 [MD] = 2.01，95%置信区间 [CI]：0.94 至 3.08，P <.05），对胰岛素抵抗指数（MD = -0.54，95% CI：-1.28 至 0.20，P =.16）、空腹血糖（MD = -0.59，95% CI：-1.50 至 0.32，P =.20）和 FINS 水平（MD = -0.30，95% CI：-0.77 至 0.17，P =.21）无显著影响。